European release of clascoterone Research/Science 4/26/2026
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
View this post in the Community →
Similar Community Posts Join
5 / 244 resultscommunity Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Clascoterone study going on right now
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
community Anyone heard about this new revolutionary news about hair loss
A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.
Related Research
6 / 99 results
research Clinical Trials and Hair Loss
Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
research Antiandrogens and Androgen Inhibitors
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
Personalized acne treatments and new therapies show promise for better results.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
Topical therapies show promise for hair loss and acne treatment with minimal side effects.
research A review of diagnosis and treatment of acne in adult female patients
Adult female acne treatment should be personalized, considering individual preferences and pregnancy, using various topical and oral medications while managing side effects and resistance.